| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_204b6251ecd19df332539e897e48d5b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 |
| filingDate |
2014-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5da86b1a6574618879a6f107eecc496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ebf7a3970f9e1614563035d67e1d425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a15dffd644ad2a71a5f9bfea1ab5f831
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36a4d0eae43ea553cf3616c7503bd481 |
| publicationDate |
2016-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016039898-A1 |
| titleOfInvention |
Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases |
| abstract |
The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11535676-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020243679-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016310574-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11135269-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11518793-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018112168-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2770003-C1 |
| priorityDate |
2013-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |